On the relationship between block of the cardiac Na+ channel and drug‐induced prolongation of the QRS complex

BACKGROUND AND PURPOSE Inhibition of the human cardiac Na+ channel (hNav1.5) can prolong the QRS complex and has been associated with increased mortality in patients with underlying cardiovascular disease. The safety implications of blocking hNav1.5 channels suggest the need to test for this activity early in drug discovery in order to design out any potential liability. However, interpretation of hNav1.5 blocking potency requires knowledge of how hNav1.5 block translates into prolongation of the QRS complex.

[1]  Derek Leishman,et al.  Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. , 2002, Current opinion in drug discovery & development.

[2]  Jean-Pierre Valentin,et al.  Reducing QT liability and proarrhythmic risk in drug discovery and development , 2010, British journal of pharmacology.

[3]  J. Madias.  Drug-induced QRS morphology and duration changes. , 2008, Cardiology journal.

[4]  B. Morgan,et al.  Cardiotoxicity after massive amantadine overdose , 2008, Journal of Medical Toxicology.

[5]  M. Molimard,et al.  Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. , 2004, Toxicology and applied pharmacology.

[6]  A. Suryaprasad,et al.  Is Wider Worse? QRS Duration Predicts Cardiac Mortality in Patients with Right Bundle Branch Block , 2008, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[7]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[8]  R. Helliwell,et al.  In vitro profiling against ion channels beyond hERG as an early indicator of cardiac risk. , 2009, Current opinion in molecular therapeutics.

[9]  R. Peri,et al.  High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology , 2008, Nature Reviews Drug Discovery.

[10]  D. Bloomfield,et al.  The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Step 5 NOTE FOR GUIDANCE ON THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON- ANTIARRHYTHMIC DRUGS (CHMP/ICH/2/04) TRANSMISSION TO CHMP , 2002 .

[11]  D. Seger.  A Critical Reconsideration of the Clinical Effects and Treatment Recommendations for Sodium Channel Blocking Drug Cardiotoxicity , 2006, Toxicological reviews.

[12]  H. Yoshida,et al.  [Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats]. , 1999, The Japanese journal of antibiotics.

[13]  N. Bayley,et al.  Failure , 1890, The Hospital.

[14]  L. Saxon,et al.  Usefulness of QRS prolongation in predicting risk of inducible monomorphic ventricular tachycardia in patients referred for electrophysiologic studies. , 2003, The American journal of cardiology.

[15]  J-P Valentin,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. , 2008, Journal of pharmacological and toxicological methods.

[16]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[17]  W. Brady,et al.  Electrocardiographic abnormalities associated with poisoning. , 2007, The American journal of emergency medicine.

[18]  Borje Darpo,et al.  ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs , 2005 .

[19]  M. Schulz,et al.  Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. , 2003, Die Pharmazie.

[20]  Michael Engwall,et al.  Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening , 2009 .

[21]  N. Akaike,et al.  Blockage of the sodium current in isolated single cells from rat ventricle with mexiletine and disopyramide. , 1985, Journal of molecular and cellular cardiology.

[22]  Borje Darpo,et al.  THEMED SECTION: QT SAFETY REVIEW The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance , 2010 .

[23]  C. Mueller,et al.  QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure , 2007, Heart.

[24]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[25]  Vijay Nambi,et al.  QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. , 2003, The American journal of cardiology.

[26]  Jean-Pierre Valentin,et al.  Value of non‐clinical cardiac repolarization assays in supporting the discovery and development of safer medicines , 2010, British journal of pharmacology.

[27]  F. Nielsen‐Kudsk,et al.  Pharmacokinetics and dynamic effects of diltiazem in the isolated guinea-pig heart. , 1988, Pharmacology & toxicology.

[28]  H. Tan,et al.  Genetic control of sodium channel function. , 2003, Cardiovascular research.

[29]  B. Small,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. , 2006, Journal of pharmacological and toxicological methods.

[30]  R. Freedman,et al.  Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. , 1992, Journal of the American College of Cardiology.

[31]  T. Sugiyama,et al.  Frequency Dependent Effects of Class I Antiarrhythmic Agents Studied in Patients with Implanted Pacemakers , 1994, Pacing and clinical electrophysiology : PACE.

[32]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[33]  Y. Kuryshev,et al.  An ion channel library for drug discovery and safety screening on automated platforms. , 2008, Assay and drug development technologies.

[34]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[35]  Jean-Pierre Valentin,et al.  Safety and secondary pharmacology: successes, threats, challenges and opportunities. , 2008, Journal of pharmacological and toxicological methods.

[36]  J. Valentin,et al.  Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspective , 2008, British journal of pharmacology.

[37]  J. Valentin,et al.  An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[38]  E. V. Vaughan Williams.  Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. , 1991, Journal of clinical pharmacology.